CABA insider transaction filings
Cabaletta Bio, Inc. — 42 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-10. Screen CABA transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-10 | 4 | Bollard Catherine — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Brun Scott C. — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Tomasello Shawn — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Simon Mark — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | HENRIQUES RICHARD C JR — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Das Arun — Chief Business Officer | Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Gerard Michael — General Counsel | Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Binder Gwendolyn — President, Science & Tech. | Grant/award (A): 225,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Chang David J. — Chief Medical Officer | Grant/award (A): 225,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Marda Anup — Chief Financial Officer | Grant/award (A): 225,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Nichtberger Steven — President & CEO, Director | Grant/award (A): 674,000 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Chang David J. — Chief Medical Officer | Purchase (P): 8,800 @ $2.26 | EDGAR |
| 2026-01-21 | 4 | Binder Gwendolyn — President, Science & Tech. | Purchase (P): 11,312 @ $2.19 | EDGAR |
| 2026-01-21 | 4 | Gavel Steve — Chief Commercial Officer | Purchase (P): 22,170 @ $2.27 | EDGAR |
| 2026-01-21 | 4 | Bollard Catherine — Director | Purchase (P): 4,405 @ $2.27 | EDGAR |
| 2026-01-21 | 4 | Gerard Michael — General Counsel | Purchase (P): 6,600 @ $2.27 | EDGAR |
| 2026-01-21 | 4 | Tomasello Shawn — Director | Purchase (P): 22,725 @ $2.21 | EDGAR |
| 2026-01-21 | 4 | Nichtberger Steven — President & CEO, Director | Purchase (P): 45,000 @ $2.24 | EDGAR |
| 2026-01-21 | 4 | Simon Mark — Director | Purchase (P): 11,061 @ $2.28 | EDGAR |
| 2025-10-15 | 4 | Gavel Steve — CHIEF COMMERCIAL OFFICER | Grant/award (A): 275,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Brun Scott C. — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Bollard Catherine — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Tomasello Shawn — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Simon Mark — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | HENRIQUES RICHARD C JR — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Brun Scott C. — Director | Disposition to issuer (D): 44,000 (derivative) @ $0 · Grant/award (A): 44,000 (derivative) @ $0 · Disposition to issuer (D): 22,000 (derivative) @ $0 · Grant/award (A): 22,000 (derivative) @ $0 · Disposition to issuer (D): 22,000 (derivative) @ $0 · Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Gerard Michael — General Counsel | Disposition to issuer (D): 100,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0 · Disposition to issuer (D): 75,000 (derivative) @ $0 · Grant/award (A): 75,000 (derivative) @ $0 · Disposition to issuer (D): 112,500 (derivative) @ $0 · Grant/award (A): 112,500 (derivative) @ $0 · +2 more | EDGAR |
| 2025-05-19 | 4 | Marda Anup — Chief Financial Officer | Disposition to issuer (D): 139,282 (derivative) @ $0 · Grant/award (A): 139,282 (derivative) @ $0 · Disposition to issuer (D): 66,463 (derivative) @ $0 · Grant/award (A): 66,463 (derivative) @ $0 · Disposition to issuer (D): 24,711 (derivative) @ $0 · Grant/award (A): 24,711 (derivative) @ $0 · +8 more | EDGAR |
| 2025-05-19 | 4 | Binder Gwendolyn — President, Science & Tech. | Disposition to issuer (D): 66,667 (derivative) @ $0 · Grant/award (A): 66,667 (derivative) @ $0 · Disposition to issuer (D): 29,908 (derivative) @ $0 · Grant/award (A): 29,908 (derivative) @ $0 · Disposition to issuer (D): 125,000 (derivative) @ $0 · Grant/award (A): 125,000 (derivative) @ $0 · +6 more | EDGAR |
| 2025-05-19 | 4 | Das Arun — Chief Business Officer | Disposition to issuer (D): 18,416 (derivative) @ $0 · Grant/award (A): 18,416 (derivative) @ $0 · Disposition to issuer (D): 35,000 (derivative) @ $0 · Grant/award (A): 35,000 (derivative) @ $0 · Disposition to issuer (D): 100,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0 · +4 more | EDGAR |
| 2025-05-19 | 4 | Bollard Catherine — Director | Disposition to issuer (D): 46,428 (derivative) @ $0 · Grant/award (A): 46,428 (derivative) @ $0 · Disposition to issuer (D): 22,000 (derivative) @ $0 · Grant/award (A): 22,000 (derivative) @ $0 · Disposition to issuer (D): 22,000 (derivative) @ $0 · Grant/award (A): 22,000 (derivative) @ $0 · +2 more | EDGAR |
| 2025-05-19 | 4 | Chang David J. — Chief Medical Officer | Disposition to issuer (D): 185,709 (derivative) @ $0 · Grant/award (A): 185,709 (derivative) @ $0 · Disposition to issuer (D): 48,836 (derivative) @ $0 · Grant/award (A): 48,836 (derivative) @ $0 · Disposition to issuer (D): 38,238 (derivative) @ $0 · Grant/award (A): 38,238 (derivative) @ $0 · +8 more | EDGAR |
| 2025-05-19 | 4 | Tomasello Shawn — Director | Disposition to issuer (D): 44,000 (derivative) @ $0 · Grant/award (A): 44,000 (derivative) @ $0 · Disposition to issuer (D): 22,000 (derivative) @ $0 · Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Nichtberger Steven — President & CEO, Director | Disposition to issuer (D): 99,714 (derivative) @ $0 · Grant/award (A): 99,714 (derivative) @ $0 · Disposition to issuer (D): 300,000 (derivative) @ $0 · Grant/award (A): 300,000 (derivative) @ $0 · Disposition to issuer (D): 333,500 (derivative) @ $0 · Grant/award (A): 333,500 (derivative) @ $0 · +6 more | EDGAR |
| 2025-05-19 | 4 | Simon Mark — Director | Disposition to issuer (D): 18,460 (derivative) @ $0 · Grant/award (A): 18,460 (derivative) @ $0 · Disposition to issuer (D): 22,000 (derivative) @ $0 · Grant/award (A): 22,000 (derivative) @ $0 · Disposition to issuer (D): 22,000 (derivative) @ $0 · Grant/award (A): 22,000 (derivative) @ $0 · +2 more | EDGAR |
| 2025-05-19 | 4 | HENRIQUES RICHARD C JR — Director | Disposition to issuer (D): 46,428 (derivative) @ $0 · Grant/award (A): 46,428 (derivative) @ $0 · Disposition to issuer (D): 22,000 (derivative) @ $0 · Grant/award (A): 22,000 (derivative) @ $0 · Disposition to issuer (D): 22,000 (derivative) @ $0 · Grant/award (A): 22,000 (derivative) @ $0 · +2 more | EDGAR |
| 2025-03-04 | 4 | Binder Gwendolyn — President, Science & Tech. | Grant/award (A): 145,000 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Marda Anup — Chief Financial Officer | Grant/award (A): 145,000 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Gerard Michael — General Counsel | Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Das Arun — Chief Business Officer | Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Chang David J. — Chief Medical Officer | Grant/award (A): 145,000 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Nichtberger Steven — President & CEO, Director | Grant/award (A): 450,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Cabaletta Bio, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-11 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-03 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-04 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-20 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-23 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CABA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →